Pacylex Pharmaceuticals Announces First Patient Dosed in a Phase 2a Study of PCLX-001 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

FDA Confirms Eligibility of XORLO™ for Accelerated Approval

RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada

Canada needs to invest now to address antimicrobial resistance

Alberta becomes the first province to list Trodelvy for triple-negative breast cancer
